Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
2 NC counties are under alert, including Johnston County.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enlivex Therapeutics Ltd
(NQ:
ENLV
)
1.230
-0.060 (-4.65%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Enlivex Therapeutics Ltd
< Previous
1
2
3
4
5
Next >
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
December 02, 2022
By Rachael Green, Benzinga
Via
News Direct
First Patients Dosed in Phase I/II Trial of Enlivex’s Off-the-Shelf Cell Therapy Candidate, AllocetraTM
December 02, 2022
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dosed in its Phase I/II clinical trial of Allocetra. The novel off-the-shelf cell therapy is designed to help break...
Via
TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
December 01, 2022
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunotherapy drug-candidate AllocetraTM.
Via
TheNewswire.com
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
December 01, 2022
By Rachael Green, Benzinga
Via
News Direct
FDA Clears Enlivex Therapeutics' IND Application To Study Allocetra™ in Patients with Advanced Solid Malignancies
November 29, 2022
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that the U.S. Food & Drug Administration (FDA) had cleared an Investigational New Drug (IND) application to study Allocetra™ in patients with...
Via
Benzinga
Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
First Patients Dosed in Phase I/II Trial of Enlivex's Off-the-Shelf Cell Therapy Candidate, AllocetraTM
November 22, 2022
On November 13, Enlivex (NASDAQ: ENLV) announced that the first patient has been dose
Via
Benzinga
Enlivex Doses First Patient in Phase I/II Trial to Evaluate Allocetra™ for Advanced Solid Tumor Treatment
November 15, 2022
Enlivex Therapeutics Ltd.
Via
Benzinga
Enlivex: Meet The Company Championing A Paradigm Shift In Cancer Treatment
November 15, 2022
Sign up for this week’s All Access giveaway here!
Via
Benzinga
Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
November 15, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex to Present at the 37th Annual Meeting of the Society For Immunotherapy Of Cancer
November 10, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
A Novel Immunotherapy That Could Bring Hope To Millions Of Sepsis Patients Received MultiCountry Clearance For Expanded Clinical Trial
November 01, 2022
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced that Israel, Spain and Greece have cleared amendments to the company’s Phase II trial protocol that will allow the study to enroll more patients.
Via
Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
October 25, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
Benzinga
Israeli Ministry Of Health Clears Way For Human Trials Of AllocetraTM, A Proprietary Off-the-Shelf Immunotherapy For Solid Tumors
October 06, 2022
The Israeli Ministry of Health (MOH) approved a Phase I/II trial of Enlivex Therapeutics Ltd.’s (NASDAQ: ENLV) proprietary immunothera
Via
Benzinga
Enlivex to Present at the 4th Macrophage-Directed Therapies Summit
October 03, 2022
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments
July 14, 2022
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and...
Via
Benzinga
Changing The Landscape Of Cancer Therapy With Macrophages? How One Israeli Company Reports It's Looking To Do Just That
July 05, 2022
One of the chief challenges cancer researchers face today is finding a way to outsmart the disease’s defense mechanisms.
Via
Benzinga
Reprogramming Imbalanced Macrophage Populations May Play A Key Role In Resolving Cancer And Various Inflammatory Disorders
June 23, 2022
Shai Novik, Executive Chairman of the Board at Enlivex Therapeutics, Ltd. (NASDAQ: ENLV), was a guest speaker at Benzinga’s All Access on June 17th, 2022.
Via
Benzinga
Monkeypox Could Reportedly Trigger An Uptick In Sepsis Cases But This Israeli Biotech Company Says It May Have Found A Treatment
June 17, 2022
As the mysterious monkeypox outbreak has many scientists on heightened alert, the rare virus could pose an additional threat to a global population still reeling from the COVID-19 pandemic.
Via
Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
June 14, 2022
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...
Via
Benzinga
Should Biotech Be On The Critical List?
May 11, 2022
The risk-off market has played havoc with the biotechs where the fundamentals have not changed as much as the valuation.
Via
Talk Markets
51 Biggest Movers From Yesterday
April 07, 2022
Gainers Advent Technologies Holdings, Inc. (NASDAQ: ADN) shares climbed 79.7% to close at $3.63 on Wednesday. Advent Technologies and Hyundai Motor Company entered into...
Via
Benzinga
World Markets News For Thursday
February 17, 2022
Ericsson stock lost another 5.27% today in US markets.
Via
Talk Markets
Inflation inflating
February 10, 2022
The Fed will be raising interest rates soon and this will chop the appeal of investments in more vulnerable yield plays.
Via
Talk Markets
Weakened Tech Stocks
February 03, 2022
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.
Via
Talk Markets
Drug Troubles
January 28, 2022
The drug sector has both good news and bad.
Via
Talk Markets
Stocks That Hit 52-Week Lows On Thursday
February 03, 2022
On Thursday, 105 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows And Highs: Meta Platforms (NASDAQ:FB) was the biggest company on...
Via
Benzinga
Market Trend: Erratic And Unreliable
December 29, 2021
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is.
Via
Talk Markets
Tuesday Markets Coverage
November 23, 2021
GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears.
Via
Talk Markets
Wednesday Market Overview
November 10, 2021
Inflation came in at 6.2% in October which boosted gold and of course the new hedge, bitcoin
Via
Talk Markets
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.